A randomised, open-label, phase 3 study
There is an interesting report of this randomised, open-label, phase 3 study at 97 medical centres in 20 countries in The Lancet
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma.
This article may be accessed via the Lancet website